Related Experiment Videos
Current developments in antithrombotic therapy: the role of antithrombin agents
1International Institute of Thrombosis and Vascular Diseases eV, Frankfurt, Germany. Breddin@em.uni-frankfurt.de
Pathophysiology of Haemostasis and Thrombosis
|June 18, 2003
Summary
Recombinant hirudin and its analogues are effective anticoagulants, particularly for preventing deep vein thrombosis and in managing acute coronary syndromes. While higher doses increase bleeding risk, these thrombin inhibitors show promise in replacing traditional anticoagulation methods.
Area of Science:
- Biochemistry
- Pharmacology
- Medicine
Background:
- Hirudin, a potent thrombin inhibitor derived from medicinal leeches, is now available through recombinant technology.
- Recombinant hirudin (r-Hirudin) and PEG-hirudin have been evaluated in numerous clinical trials for anticoagulant therapy.
Purpose of the Study:
- To review the clinical applications and efficacy of hirudin and its analogues as anticoagulants.
- To assess the role of thrombin inhibitors in various medical conditions, including thrombosis and heparin-induced thrombocytopenia.
Main Methods:
- Review of clinical trials and studies involving hirudin, bivalirudin, argatroban, and melagatran.
- Analysis of efficacy and safety data, including bleeding risk and specific patient outcomes.
Main Results:
- Hirudin demonstrates superior efficacy over low molecular weight heparin in preventing deep venous thrombosis post-hip replacement.
- Bivalirudin showed a significant reduction in reinfarction rates in acute myocardial infarction patients, though not mortality.
- Hirudin and argatroban are effective in managing heparin-induced thrombocytopenia type II.
- Oral thrombin inhibitors, like melagatran, show promising results in combination with other administration routes for orthopedic surgery patients.
Conclusions:
- Thrombin inhibitors, including hirudin and its analogues, represent a significant advancement in anticoagulation therapy.
- These agents are effective in various clinical scenarios and are likely to become standard treatments for several indications, potentially replacing existing anticoagulants.